Phase III

Phase III Confirmatory Review — NTX-101

Confirmatory time-to-clinical-worsening analysis and integrated safety interpretation for NTX-101.

Integrated report Program overview Data lineage Model review Phase I Phase II Phase III

Kaplan-Meier view

KM plot

Event summary by arm

ArmSubjectsEventsMedian time (days)
ntx101_high 61 48 214.34
ntx101_low 54 42 141.965
placebo 48 42 96.945

Hypothesis summary

ComparisonHazard ratio95% CILog-rank p-valueMedian delay (days)High dose pLow dose p
Active vs placebo time to worsening 0.685 [0.47, 0.998] 0.0421 83.575 0.0455 0.1422
Disclaimer: This review includes analyses derived from a combination of publicly available structural source data and documented synthetic continuity extensions for the fictional NTX-101 program. It is intended for internal methodological demonstration only and is not intended for external publication, regulatory submission, or treatment decision-making.